A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a phase III, randomized, double-blinded, multicenter clinical study to evaluate the
efficiency and safety of AK105 (Anti-PD1 antibody) plus paclitaxel and carboplatin vs placebo
plus paclitaxel and carboplatin as First-line Therapy in patients with metastatic squamous
non-small cell lung cancer.